Page 6 - genveon oznur

L. Elmer et al. / Journal of the Neurological Sciences 248 (2006) 78–83 83

[31] Brooks DJ, Sagar Hthe UK-Irish Entacapone Study Group. [35] Myllyla VV, Sotaniemi KA, Hakulinen P, Maki-Ikol O, Heinonen EH.
Entacapone is beneficial in both fluctuating and non-fluctuating Selegiline as the primary treatment of Parkinson’s disease — a long-
patients with Parkinson’s disease: a randomised, placebo controlled, term double-blind study. Acta Neurol Scand 1997;95:211–8.
double blind, six month Study. J Neurol Neurosurg Psychiatry [36] Shoulson Ithe Parkinson Study Group. An interim report of the effect
2003;74:1071–9. of selegiline (L-deprenyl) on the progression of disability in early
[32] Rinne UK, Larsen JP, Siden A, Worm-Petersen Jthe Nomecomt Study Parkinson’s disease. Eur Neurol 1992;32(Suppl. 1):46–53.
Group. Entacapone enhances the response to levodopa in Parkinsonian [37] Montastruc JL, Chaumerliac C, Desboeuf K, Manika M, Bagheri
patients with motor fluctuations. Neurology 1998 (Nov.);51(5):1309–14. H, Rascol O, et al. Adverse drug reactions to selegiline: a review
[33] Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, of the French pharmacovigilance database. Clin Neuropharmacol
Celomen Study Group. Efficacy and safety of entacapone in 2000 (Sep.–Oct.);23(5):271–5.
Parkinson’s disease patients with suboptimal levodopa response: a 6- [38] Lambert D, Waters CH. Comparative tolerability of the newer
month randomized placebo-controlled double-blind study in Germany generation antiparkinsonian agents. Drugs Aging 2000 (Jan.);16(1):
and Austria (Celomen study). Acta Neurol Scand 2002;105:245–55. 55–65.
[34] Fenelon G, Gimenez-Roldan S, Montastruc JL, Bermejo F, Durif F, [39] Kamakura K, Mochizuki H, Kaida K, Hirata A, Kanzaki M, Masaki T,
Bourdeix I, et al. Efficacy and tolerability of entacapone in patients et al. Therapeutic factors causing hallucination in Parkinson’s disease
with Parkinson’s disease treated with levodopa plus a dopamine agonist patients, especially those given selegiline. Parkinsonism Relat Disord
and experiencing wearing-off motor fluctuations. A randomized, 2004 (Jun.);10(4):235–42.
double-blind, multicentre study. J Neural Transm 2003;110:239–51.